Deutsche Bank Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $36
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $30 to $36.
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $30 to $36.